Similar companies
Did Monte Rosa Therapeutics Beat Earnings?
Monte Rosa Therapeutics (GLUE) reported Q1 '25 revenue of $85M, up 7,882.0% year-over-year, with reported EPS of $0.57. That topped the $-0.32 analyst estimate by 278.1% — an earnings beat.
AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Monte Rosa Therapeutics’s job postings, web traffic, and employee business outlook. See the full GLUE stock analysis or the earnings calendar for upcoming reports.
Monte Rosa Therapeutics Quarterly Financial Trends
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.2M | 61M | 85M | 23M | 13M | 2.8M | 4.2M | 9M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 51.8% | 100.0% |
| Operating margin | -287.8% | 21.4% | 51.9% | -67.1% | -258.3% | -1,787.7% | -1,188.5% | -547.8% |
| Net income | -24M | 13M | 47M | -12M | -27M | -46M | -45M | -43M |
| Net margin | -258.9% | 22.2% | 55.2% | -53.0% | -212.1% | -1,658.9% | -1,057.1% | -483.9% |
| EPS | — | — | $0.57 | — | — | — | — | — |
Monte Rosa Therapeutics Earnings Trend Analysis
Over the eight quarters from Q3 '24 to Q2 '26, Monte Rosa Therapeutics’s quarterly revenue moved from $9.2M to $9M. Net margin compressed from -258.9% to -483.9%, against a 100% gross margin in the most recent quarter — a read on whether revenue growth is translating into profit. Monte Rosa Therapeutics has beaten Wall Street EPS estimates in 1 of its last 1 reported quarters.
When Is Monte Rosa Therapeutics’s Next Earnings Date?
Monte Rosa Therapeutics reports earnings on a quarterly schedule. Its most recent report covered Q1 '25. For the confirmed upcoming date — and every other company reporting soon — see the GLUE earnings calendar.
Frequently Asked Questions: Monte Rosa Therapeutics Earnings
Monte Rosa Therapeutics's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.
Monte Rosa Therapeutics reported Q1 '25 EPS of $0.57 on revenue of $85M (+7,882.0% YoY). Monte Rosa Therapeutics beat estimates, reporting $0.57 vs. the $-0.32 estimate.
Monte Rosa Therapeutics reported Q1 '25 revenue of $85M, up 7,882.0% from the same quarter a year earlier.
Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the GLUE AI Score.
